TY - JOUR T1 - Orbital metastasis: Clinical presentation and survival in a series of 11 cases JO - Archivos de la Sociedad Española de Oftalmología (English Edition) T2 - AU - Montejano-Milner,R. AU - López-Gaona,A. AU - Fernández-Pérez,P. AU - Sánchez-Orgaz,M. AU - Romero-Martín,R. AU - Arbizu-Duralde,A. SN - 21735794 M3 - 10.1016/j.oftale.2020.07.014 DO - 10.1016/j.oftale.2020.07.014 UR - https://www.elsevier.es/en-revista-archivos-sociedad-espanola-oftalmologia-english-496-articulo-orbital-metastasis-clinical-presentation-survival-S2173579420302255 AB - Background and objectiveOrbital metastases are an uncommon condition. They may be the clinical presentation of a previously unknown malignancy. Depending on the series, the rate of orbital metastasis as a first manifestation of a malignant tumour is 20%–42%. The clinical presentation and survival is presented in a series of 11 cases of orbital metastasis corresponding to 10 patients. Material and methodsDescriptive retrospective study of a series of 10 adult patients diagnosed with orbital metastasis from solid tumours during a 9-year period. Metastasis involving the orbit was included, and lymphomas and contiguity invasions from adjacent structures were excluded. A note was made on whether the clinical picture was the first sign of tumour onset. Signs and symptoms at clinical debut were registered, as were primary tumour location, distance seeding, orbital structures involved, and survival time since the diagnosis was established. ResultsOne-half (50%) of the patients were women. Mean age at diagnosis was 60.9 years (range 42–82). In nine cases (90%), the metastasis was unilateral, while in the remaining one the involvement was bilateral. The most frequent primary tumour location was the breast (36% of the cases); followed by the bladder (27%), lung (18%), and ovary and cavum (9%). Seventy percent of the patients had a previously diagnosed neoplasm; in 3 cases the metastasis was the first malignancy manifestation. Most frequent symptoms were diplopia (60%), visual impairment (40%), and pain (30%). The most common signs were resistance to ocular retropulsion (60%), presence of a mass on orbital palpation, and ocular dystopia (50%), and bulbar hyperaemia and proptosis (40%). The most employed management modality was clinical observation (5 patients). In 3 patients radiotherapy was administered, combining chemotherapy plus hormonal therapy in one case, and orbital exenteration in another one. In 2 cases, chemotherapy was administered as an isolated regime. Median survival time was 4.8 months since the diagnosis. There was a statistically significant difference between the survival time in the observation group (median 2.5 months) and in the active treatment group (median 29.2 months), p=.034. ConclusionsIn the series presented, 27% of the cases established the clinical debut of the malignant neoplasm. The ophthalmologist plays an essential role when this condition is suspected, diagnosing it, and proposing its management together with the Oncology Service. ER -